Moma Therapeutics

MOMA Therapeutics aims to discover the next generation of precision medicines by targeting molecular machines that underlie human diseases. Molecular machines are complex protein structures within cells that perform essential biological functions. By understanding and manipulating these machines, MOMA seeks to develop drugs that can precisely target disease mechanisms.

The company serves a broad range of clients, including pharmaceutical companies, healthcare providers, and potentially patients who will benefit from these advanced treatments. MOMA's business model revolves around leveraging seminal scientific advancements in biochemistry, biophysics, structural biology, chemistry, and functional genomics. Functional genomics is the study of gene functions and interactions, which helps in identifying potential drug targets.

MOMA Therapeutics generates revenue primarily through partnerships, collaborations, and funding from investors. The company recently secured $150 million in Series B funding, which is a significant investment round that helps startups grow. This funding will support their research and development efforts, enabling them to bring new precision medicines to market.

The company's team is described as "collectively unstoppable," emphasizing their collaborative and innovative approach. With a robust team of scientists and access to 400 molecular machines, MOMA is well-positioned to make significant advancements in drug discovery.

In summary, MOMA Therapeutics is a biotech startup dedicated to discovering precision medicines by targeting molecular machines, serving pharmaceutical companies and healthcare providers, and generating revenue through partnerships and investor funding.